TRPH 395
Alternative Names: TRPH-395Latest Information Update: 28 Feb 2023
At a glance
- Originator Ontario Institute for Cancer Research
- Developer Triphase Accelerator Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action WDR5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Canada
- 28 Feb 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb